We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+5.61%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$287M
AUM Growth
-$3.65M
Cap. Flow
+$64.2M
Cap. Flow %
22.39%
Top 10 Hldgs %
66.86%
Holding
42
New
13
Increased
6
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.6M
2
GILD icon
Gilead Sciences
GILD
+$15.8M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$12.3M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$11.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$11M

Top Sells

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$10.2M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$5.54M
3
DERM
Dermira, Inc.
DERM
+$4.42M
4
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$4.16M
5
IBRX icon
ImmunityBio
IBRX
+$3.81M

Sector Composition

Rank Sector Weight
1 Healthcare 86.13%
2 Miscellaneous 13.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$30M 10.48%
1,404,055
+146,000
+12% +$3.26M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$28.9M 10.09%
3,424,104
-91,507
-3% -$648K
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.5B
$22.9M 7.98%
+277,272
New +$22.6M
SRPT icon
4
Sarepta Therapeutics
SRPT
$2.18B
$22.5M 7.87%
1,155,000
+651,993
+130% +$11.4M
GILD icon
5
Gilead Sciences
GILD
$180B
$16.1M 5.62%
+175,400
New +$15.8M
NBIX icon
6
Neurocrine Biosciences
NBIX
$15.6B
$16M 5.59%
405,320
+278,320
+219% +$11M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$4.1B
$15.9M 5.54%
3,125,198
-62,409
-2% -$342K
CPXX
8
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$15.6M 5.45%
+1,416,257
New +$4.64M
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$12.4M 4.34%
+270,665
New +$9.82M
BMY icon
10
Bristol-Myers Squibb
BMY
$130B
$11.2M 3.9%
+175,000
New +$11M
AGEN
11
Agenus
AGEN
$311M
$9.99M 3.48%
122,324
+10,278
+9% +$693K
ANAC
12
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$8.91M 3.11%
+166,700
New +$12.3M
NDRM
13
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$7.59M 2.65%
537,477
+17,455
+3% +$236K
VNDA icon
14
Vanda Pharmaceuticals
VNDA
$303M
$7.14M 2.49%
854,579
-406,230
-32% -$3.33M
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$6.61M 2.3%
+150,000
New +$6.02M
SRNE
16
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$6.16M 2.15%
1,145,779
-800
-0.1% -$4.65K
CASC
17
DELISTED
Cascadian Therapeutics, Inc.
CASC
$5.17M 1.8%
678,179
-8,333
-1% -$64.2K
TLGT
18
DELISTED
Teligent, Inc
TLGT
$4.53M 1.58%
92,500
-44,829
-33% -$2.8M
LJPC
19
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.43M 1.54%
211,672
-572,527
-73% -$10.2M
FBIO icon
20
Fortress Biotech
FBIO
$82.7M
$4.15M 1.45%
89,191
– –
PTX
21
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$4.08M 1.42%
388,990
-125,502
-24% -$2.49M
VCYT icon
22
Veracyte
VCYT
$3.3B
$3.94M 1.38%
730,514
-10,839
-1% -$64.1K
DERM
23
DELISTED
Dermira, Inc.
DERM
$3.62M 1.26%
175,000
-179,950
-51% -$4.42M
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.3M 1.15%
+208,086
New +$3.7M
IMMU
25
DELISTED
Immunomedics Inc
IMMU
$2.63M 0.92%
+1,050,457
New +$2.36M
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Avoro Capital Advisors held 42 positions worth $287M, down 1.3% from $290M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Avoro Capital Advisors deployed $64.2M of net new capital in Q1 2016, opening 13 new positions and adding to 6 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 277,272 shares worth $22.9M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was La Jolla Pharmaceutical Company, an estimated $10.2M trimmed.

  • Avoro Capital Advisors's largest Q1 2016 buy was BioMarin Pharmaceuticals: 277,272 shares worth $22.9M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $11.4M increase.
  • Avoro Capital Advisors's biggest Q1 2016 reduction was La Jolla Pharmaceutical Company, cutting an estimated $10.2M.
  • Avoro Capital Advisors fully exited Sio Gene Therapies Inc. Common Stock in Q1 2016, selling an estimated $5.54M.
  • Avoro Capital Advisors's ten largest holdings make up 67% of its $287M portfolio in Q1 2016.
  • Avoro Capital Advisors opened 13 new positions and closed 4 in Q1 2016.
  • Avoro Capital Advisors's portfolio value fell 1.3% quarter-over-quarter to $287M.

Based on Avoro Capital Advisors's 13F filing for Q1 2016, filed 16 May 2016.